HC Wainwright Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA)

HC Wainwright reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA - Free Report) in a report published on Monday,Benzinga reports. HC Wainwright currently has a $18.00 price target on the stock.

Several other brokerages have also recently issued reports on COYA. Wall Street Zen cut Coya Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. D. Boral Capital reiterated a "buy" rating and set a $18.00 price target on shares of Coya Therapeutics in a research note on Tuesday, April 22nd. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $17.00.

Coya Therapeutics Price Performance

NASDAQ COYA traded down $0.26 during trading hours on Monday, hitting $5.37. The company's stock had a trading volume of 181,021 shares, compared to its average volume of 72,135. Coya Therapeutics has a 12 month low of $4.65 and a 12 month high of $10.24. The company's 50 day simple moving average is $5.77 and its two-hundred day simple moving average is $6.04. The company has a market cap of $89.81 million, a P/E ratio of -8.26 and a beta of 0.22.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.44). The company had revenue of $257.88 million for the quarter, compared to analysts' expectations of $2.63 million. As a group, research analysts predict that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC grew its position in shares of Coya Therapeutics by 1,005.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock valued at $30,000 after purchasing an additional 4,777 shares in the last quarter. XTX Topco Ltd bought a new position in Coya Therapeutics during the fourth quarter valued at approximately $59,000. Charles Schwab Investment Management Inc. purchased a new position in Coya Therapeutics during the 1st quarter valued at approximately $65,000. Jane Street Group LLC purchased a new stake in shares of Coya Therapeutics during the 4th quarter worth approximately $74,000. Finally, Northern Trust Corp increased its position in Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company's stock worth $164,000 after purchasing an additional 3,099 shares during the last quarter. Institutional investors own 39.75% of the company's stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.